Roche Diagnostics Corp recently announced the establishment of a strategic alliance with Pathology Inc, Torrance, Calif, that designates the company as a Roche Molecular Center of Excellence (MCOE) for the next five years.
Established in 2002, Roche’s MCOE program is designed to create an alliance network that enables noncompeting regional laboratories across the US to collaborate and capitalize on scientific knowledge in molecular testing and, in turn, help accelerate the advancement of new test methods and technology.
Pathology Inc is one of 35 labs in the US that have received the MCOE recognition and joined in a strategic partnership with Roche. “This relationship with Roche will help keep Pathology Inc on the leading edge of women’s health services, and will help ensure that we are supporting physicians and their patients with the most advanced molecular technologies,” said Vicki DiFrancesco, president and CEO of Pathology Inc. “It will also integrally support our mission to help doctors personalize patient care.”
Pathology Inc is the country’s premier full-service independent women’s health laboratory, providing expertise in reproductive FDA donor testing as well as anatomic, molecular, and digital pathology services. The laboratory’s integrated diagnostic services help doctors personalize patient care to optimally treat disease and maintain health and wellness. The company is committed to providing only the highest level of testing quality and service, and working with physicians to provide unique solutions to their most challenging needs.
“Roche is very pleased to welcome Pathology Inc into the Molecular Center of Excellence alliance,” said Whitney Green, senior vice president for molecular diagnostics at Roche Diagnostics. “We value their expertise in women’s health and look forward to working together in implementing molecular technologies in the advancement of personalized medicine.”
As a nationally recognized Roche MCOE, the Pathology Inc molecular diagnostics laboratory will offer physicians and patients some of the latest and most advanced molecular technologies, such as Roche’s Cobas HPV Test, a screening test approved by FDA for use in helping clinicians assess patients’ risk of cervical cancer based on the presence of clinically relevant high-risk HPV DNA.